Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …

Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

Background We update recommendations on 12 topics that were in the 9th edition of these
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …

Introduction It is unclear if direct oral anticoagulants (DOACs) are effective and safe
alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …

Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity
and mortality. VTE prevention and treatment are more complex in patients with cancer. The …

Heparin has been recognized as a valuable anticoagulant and antithrombotic for several
decades and is still widely used in clinical practice for a variety of indications. The …

Venous thromboembolism (VTE), including deep‐vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in cancer patients. Patients with cancer …

Venous thromboembolism (VTE) is a highly prevalent complication of malignancy with
emerging changes in incidence, diagnosis and treatment paradigms. This manuscript …